XTT Formazan Widely Used to Detect Cell Viability Inhibits HIV Type 1 Infectionin Vitroby Targeting gp41
- 20 September 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 18 (14) , 989-997
- https://doi.org/10.1089/08892220260235353
Abstract
XTT can be metabolically reduced by mitochondrial dehydrogenase in viable cells to a water-soluble formazan product. Thus XTT has been widely used to evaluate cell viability and to screen anti-HIV agents and the cytotoxicity of these agents. The present studies demonstrated that XTT formazan derived from XTT in cell culture significantly inhibits the fusion of HIV-1-infected cells with uninfected cells. Synthetic XTT formazan effectively inhibited the replication of laboratory-adapted and primary HIV-1 isolates and cell-to-cell fusion with low cytotoxicity. It blocks the six-helix bundle formation between peptides derived from the N- and C-terminal heptad repeat regions of the gp41 ectodomain (designated N- and C-peptides, respectively). Analysis by a computer-aided docking program indicates that XTT formazan may bind to the highly conserved hydrophobic pocket on the surface of the central trimeric coiled coil of gp41. These results suggest that XTT formazan inhibits HIV-1 entry by targeting the α-helical coiled-coil domain of gp41. This small molecular nonpeptide antiviral compound can be used as a lead for designing more effective HIV-1 entry inhibitors targeting the fusion stage of HIV-1 infection. But because XTT formazan itself has anti-HIV-1 activity, caution should be exercised when XTT is used to evaluate HIV-1 infectivity.Keywords
This publication has 36 references indexed in Scilit:
- A Fusion Inhibitor (FP‐21399) for the Treatment of Human Immunodeficiency Virus Infection: A Phase I StudyThe Journal of Infectious Diseases, 2000
- A Salt Bridge between an N-terminal Coiled Coil of gp41 and an Antiviral Agent Targeted to the gp41 Core Is Important for Anti-HIV-1 ActivityBiochemical and Biophysical Research Communications, 2000
- Development of HIV Entry Inhibitors Targeted to the Coiled-Coil Regions of gp41Biochemical and Biophysical Research Communications, 2000
- Structure-Based Identification of Small Molecule Antiviral Compounds Targeted to the gp41 Core Structure of the Human Immunodeficiency Virus Type 1Journal of Medicinal Chemistry, 1999
- Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4The Journal of Experimental Medicine, 1997
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.The Journal of Experimental Medicine, 1991
- New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral ActivityJNCI Journal of the National Cancer Institute, 1989
- The synthesis of XTT: A new tetrazolium reagent that is bioreducible to a water‐soluble formazanJournal of Heterocyclic Chemistry, 1988
- CHARMM: A program for macromolecular energy, minimization, and dynamics calculationsJournal of Computational Chemistry, 1983